Veloxis submits sNDA to FDA seeking new indication for ENVARSUS XR

Veloxis Pharmaceuticals asserted that it has submitted a supplemental New Drug Application to the U.S Food and Drug Administration seeking new indication for ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants.

The indication is namely De Novo indication. The sNDA is based on data from multinational phase 3 study LCP-Tacro 3002, which evaluated the safety and efficacy of Envarsus XR compared to immediate-release tacrolimus capsules for the prevention of acute allograft rejection in over 500 de novo adult kidney transplant recipients.  The primary endpoint was the incidence of treatment failures within 12 months.  Treatment failure was a composite endpoint that included death, graft failure, biopsy-proven acute rejection or lost to follow-up.

Craig Collard, CEO of Veloxis Pharmaceuticals A/S said, “We are excited to re-file for the de novo indication for ENVARSUS XR and look forward to working with FDA as it reviews our filing.”

ENVARSUS XR was sanctioned by the FDA on the 10th July 2015 for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants. Veloxi’s original NDA for ENVARSUS XR sought approval for the de novo indication and was filed on 30 December 2013.

FDA tentatively approved ENVARSUS XR for the de novo indication on 30 October 2014; however, final approval was blocked by the exclusivity of ASTAGRAF XL which expired on 19 July 2016.